CAS 1210344-57-2
:Ertugliflozin
Description:
Ertugliflozin is a medication primarily used in the management of type 2 diabetes mellitus. It belongs to the class of drugs known as sodium-glucose co-transporter 2 (SGLT2) inhibitors, which function by preventing the reabsorption of glucose in the kidneys, thereby promoting its excretion in urine and lowering blood glucose levels. The chemical formula of Ertugliflozin reflects its structure, which includes a glucose moiety linked to a specific aromatic ring system. This compound is characterized by its ability to improve glycemic control and may also contribute to weight loss and cardiovascular benefits in diabetic patients. Additionally, Ertugliflozin has been studied for its potential effects on renal function. Common side effects may include urinary tract infections and genital mycotic infections, which are associated with increased glucose in the urine. As with any medication, it is essential for patients to consult healthcare professionals for personalized advice and monitoring while using Ertugliflozin.
Formula:C22H25ClO7
InChI:InChI=1S/C22H25ClO7/c1-2-28-16-6-3-13(4-7-16)9-14-10-15(5-8-17(14)23)22-20(27)18(25)19(26)21(11-24,30-22)12-29-22/h3-8,10,18-20,24-27H,2,9,11-12H2,1H3/t18-,19-,20+,21-,22-/m0/s1
InChI key:InChIKey=MCIACXAZCBVDEE-CUUWFGFTSA-N
SMILES:O[C@H]1[C@@]2(O[C@@](CO)(CO2)[C@@H](O)[C@@H]1O)C3=CC(CC4=CC=C(OCC)C=C4)=C(Cl)C=C3
Synonyms:- (1S,2S,3S,4R,5S)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol
- 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-beta-L-idopyranose
- 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-β-<span class="text-smallcaps">L</span>-idopyranose
- Cc-212
- Mk 8835
- Pf 04971729-00
- Pf-04971729
- β-<span class="text-smallcaps">L</span>-Idopyranose, 1,6-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-
- Ertugliflozin
- β-L-Idopyranose, 1,6-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-
- 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-β-L-idopyranose
- PF04971729;PF 04971729 (ERTUGLIFLOZIN)
- Ertugliflozin Base
- 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-beta-L-idopyranose PF-04971729(Ertugliflozin)
- PF-04971729/Ertugliflozin
- (1S,2S,3S,4R,5S)-(2,3,4-TRIS-BENZYLOXY-5-(4-CHLORO-3-(4-ETHOXY-BENZYL)-PHENYL)-68-DIOXA-BICYCLO(3.2.1)OCT-1-YL)-METHANOL
- Ertugliflozin, >=98%
- (1S,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol
- Ertugliflozin/PF-04971729
- PF-04971729 USP/EP/BP
- CS-186
- ERTUGLIFLOZIN;PF04971729;PF 04971729
- Ertugliflozin : PF 04971729-00
- Leuco methylthioninium
- Ertugliflozin MK-8835
- See more synonyms
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 7 products.
1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-β-L-idopyranose
CAS:Formula:C22H25ClO7Purity:98%Color and Shape:SolidMolecular weight:436.8827(1S,2S,3S,4R,5S)-5-(4-Chloro-3-(4-Ethoxybenzyl)Phenyl)-1-(Hydroxymethyl)-6,8-Dioxabicyclo[3.2.1]Octane-2,3,4-Triol
CAS:(1S,2S,3S,4R,5S)-5-(4-Chloro-3-(4-Ethoxybenzyl)Phenyl)-1-(Hydroxymethyl)-6,8-Dioxabicyclo[3.2.1]Octane-2,3,4-TriolPurity:98%Molecular weight:436.88g/molErtugliflozin
CAS:PF-04971729 (Ertugliflozin (PF-04971729)) is a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2).Formula:C22H25ClO7Purity:99.89% - 99.96%Color and Shape:SolidMolecular weight:436.88Ertugliflozin (PF 04971729)
CAS:<p>Ertugliflozin is a novel, selective, and potent inhibitor of SGLT2. It is being developed for the treatment of type 2 diabetes and associated conditions such as hypertension, dyslipidemia and cardiovascular complications. Ertugliflozin selectively inhibits the renal glucose transporter SGLT2 to reduce urinary glucose excretion. In clinical trials ertugliflozin has been shown to significantly lower HbA1c levels in patients with type 2 diabetes mellitus. The drug was well tolerated in clinical trials with no clinically relevant adverse events observed. This agent has also been shown to decrease blood pressure in patients with type 2 diabetes mellitus and normotensive subjects.</p>Formula:C22H25ClO7Purity:Min. 96 Area-%Color and Shape:White Off-White PowderMolecular weight:436.88 g/mol





